SBIR Phase I: COVID-19 Rapid Sensing Using Structural DNA Biosensor

SBIR 第一阶段：使用结构 DNA 生物传感器快速传感 COVID-19

• 批准号: 2027816
• 负责人: Xiaohu Yao
• 金额: $ 24.84万
• 依托单位: ATOM BIOWORKS INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2027816&HistoricalAwards=false
• 关键词: SBIR; Phase; COVID; 19; Rapid

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project will be the development of a new rapid COVID-19 virus diagnostic system that recognizes specific virus surface characteristics and generates accurate results within minutes. The current viral diagnostics standard involves complex instruments and technical expertise to run, taking hours to produce and interpret a result. The proposed technology is a sensor that selectively interacts with the COVID-19 virus to produce visible results without expensive instruments or time-consuming procedures. The fundamental technology can also be adapted to rapidly and cheaply develop new diagnostic tests. The lower cost of the test and faster sample-to-result time will greatly improve disease measurement and control, supporting public health needs. This project proposes to develop a highly functional, sensitive and specific diagnostic for the diagnosis of coronavirus based on a Pattern-Recognition Enhanced Sensing and Therapeutics (PEST) concept. The proposed diagnostic solution uses algorithmically designed structural DNA to form a trap that will detect the “signature pattern” of the pathogen and selectively bind to it to generate a signal, without the need of DNA/RNA preprocessing or amplification associated with the current state of practice. The proposed work is to build a pre-clinical prototype of PEST-enabled lateral flow-based COVID-19 rapid diagnostics; the technical performance goal is a sample-to-result time of 5 minutes. The proposed work will also perform pre-clinical validation to validate its specificity and detection limit, as well as implement mechanisms to improve the assay specificity to avoid cross-reaction to other virus types in the Coronavirus family.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究第一阶段项目的更广泛的影响/商业潜力将是开发一种新的快速新冠肺炎病毒诊断系统，该系统可以识别特定的病毒表面特征，并在几分钟内产生准确的结果。目前的病毒诊断标准涉及复杂的仪器和技术专业知识，需要数小时才能产生和解释结果。这项拟议的技术是一种传感器，可以选择性地与新冠肺炎病毒相互作用，产生可见的结果，而不需要昂贵的仪器或耗时的程序。这项基础技术还可以被用来快速而廉价地开发新的诊断测试。更低的检测成本和更快的样本到结果时间将极大地改进疾病测量和控制，支持公共卫生需求。该项目建议开发一种基于模式识别增强传感和治疗(PEST)概念的高度功能性、敏感性和特异性的冠状病毒诊断方法。建议的诊断解决方案使用算法设计的结构DNA来形成陷阱，该陷阱将检测病原体的“特征模式”，并选择性地与其结合以产生信号，而不需要与当前实践状态相关的DNA/RNA预处理或放大。拟议的工作是构建基于PEST的基于侧向流动的新冠肺炎快速诊断的临床前原型；技术性能目标是样本到结果的时间为5分钟。这项拟议的工作还将进行临床前验证，以验证其特异性和检测极限，并实施机制以提高分析特异性，以避免与冠状病毒家族中其他类型的病毒发生交叉反应。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。